⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bromoethane SCHEMBL1331135 | 0.80 | — | — | |
| Bromoethane SCHEMBL703294 | 0.78 | — | — | |
| Bromoethane SCHEMBL703843 | 0.74 | — | — | |
| N-Propyl Bromide SCHEMBL795887 | 0.70 | — | — | |
| N-Propyl Bromide SCHEMBL795760 | 0.70 | — | — | |
| N-Propyl Bromide SCHEMBL796355 | 0.70 | — | — | |
| Bromoethane SCHEMBL18911564 | 0.70 | — | — | |
| Dibromomethane SCHEMBL20701 | 0.65 | — | — | |
| N-Propyl Bromide SCHEMBL796556 | 0.64 | — | — | |
| SCHEMBL1332728 | 0.64 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 75 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4658639-A1 | N,N-DIALKYL-4-(2-ETHYLINDAN-2-YL)-1H-IMIDAZOLE-1-CARBOXAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF NEURODEGENERATIVE DISEASES | Univerza V Ljubljani (SI) | 2025-12-10 | — | — | EP | disclosed |
| EP-4630115-A1 | THERAPEUTIC COMPOUNDS | Sanofi (FR) | 2025-10-15 | — | — | EP | disclosed |
| EP-4143195-B1 | IMIDAZOPYRIDAZINES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-05-21 | — | — | EP | disclosed |
| US-20250122181-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2025-04-17 | — | — | US | disclosed |
| US-20250115597-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO LTD (CN) | 2025-04-10 | — | — | US | disclosed |
| US-12240812-B2 | Compound for inhibiting PGE2/EP4 signaling transduction inhibiting, preparation method therefor, and medical uses thereof | Keythera (Suzhou) Pharmaceuticals Co. Ltd. (CN) | 2025-03-04 | — | — | US | disclosed |
| US-12202836-B2 | Bicyclic-fused heteroaryl or aryl compounds | PFIZER INC. (US) | 2025-01-21 | — | — | US | disclosed |
| WO-2024235205-A1 | THIAZOLE DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2024-11-21 | — | — | WO | disclosed |
| US-20240376085-A1 | BENZIMIDAZOLES AS MODULATORS OF IL-17 | JANSSEN PHARMACEUTICA NV (BE) | 2024-11-14 | — | — | US | disclosed |
| US-12129250-B2 | TYK2 inhibitors and compositions and methods thereof | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2024-10-29 | — | — | US | disclosed |
| US-20100105755-A1 | SUBSTITUTED BENZAMIDE MODULATORS OF DOPAMINE RECEPTOR | AUSPEX PHARMACEUTICALS, INC. (US) | 2010-04-29 | — | — | US | disclosed |
| US-20090062298-A1 | DEUTERIUM-ENRICHED SILDENAFIL | PROTIA, LLC (US) | 2009-03-05 | — | — | US | disclosed |
| WO-2008157272-A2 | DEUTERIUM-ENRICHED TAMSULOSIN | PROTIA LLC (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080312328-A1 | DEUTERIUM-ENRICHED TAMSULOSIN | PROTIA, LLC (US) | 2008-12-18 | — | — | US | disclosed |
| US-20050053552-A1 | Phase shift colloids as ultrasound contrast agents | QUAY STEVEN C (US) | 2005-03-10 | — | — | US | disclosed |
| US-6569404-B1 | Aqueous colloidal suspension, dispersed phase is gas microbubbles of perfluoropropane, perfluorobutane, perfluoropentane, perfluorohexane or sulfur hexafluoride; fluorinated amphiphile for stabilizing microbubbles | AMERSHAM HEALTH A/S (NO) | 2003-05-27 | — | — | US | disclosed |
| US-6245319-B1 | Colloidal dispersions of perfluoropentane | SONUS PHARMACEUTICALS, INC. | 2001-06-12 | — | — | US | disclosed |
| EP-0680341-B1 | PHASE SHIFT COLLOIDS AS ULTRASOUND CONTRAST AGENTS | SONUS PHARMA INC (US) | 2001-05-09 | — | — | EP | disclosed |
| EP-1038535-A2 | Use of selected perfluorocarbons for the preparation of diagnostic ultrasound contrast agents | SONUS PHARMACEUTICALS, INC. (US) | 2000-09-27 | — | — | EP | disclosed |
| US-4009208-A | N,N'-HEPTAMETHYLENEBIS(4-METHOXYBENZAMIDE) | STERLING DRUG INC. (US) | 1977-02-22 | — | — | US | disclosed |